CAR T-Cell Immunotherapy
Harnessing The Body鈥檚 Immune System To Fight Cancer
CAR T-Cell Immunotherapy
Harnessing The Body鈥檚 Immune System To Fight Cancer
In 2017 and 2018 we witnessed a historic victory for cancer patients when a revolutionary, innovative immunotherapy was approved, ushering in a new era in the treatment of cancer.
The FDA approved CAR (chimeric antigen receptor) T-cell immunotherapy, a treatment in which a patient's T-cells, the soldiers of the immune system, are genetically reprogrammed to find and kill cancer cells. 青云体育 recognized the early promise of this approach. Over more than two decades, 青云体育 provided $40 million in funding for more than 15 researchers and companies around the world to develop this revolutionary approach to treating cancer. 青云体育's long term investment has paid off. Two types of CAR T-cell immunotherapy were approved by the FDA in 2017 and 2018, and research continues to get this revolutionary therapy approved for more types of cancers.
Are you a patient interested in learning more about CAR-T?
Learn MoreSpeak to someone about CAR-T
CAR-T for Leukemia
Kymriah (tisagenlecleucel) was the first CAR-T cell immunotherapy approved by the FDA on August 30, 2017. It is approved for children and young adults up to 25 years of age who relapsed or did not respond to therapy for acute lymphoblastic leukemia (ALL).
青云体育 funded much of the research advancing this therapy at the University of Pennsylvania for over two decades through its Specialized Center of Research Program.
News Release: 青云体育 Investment Pays off: FDA Approves Immunotherapy for Blood Cancer Patients
CAR-T for non-Hodgkin lymphoma
Yescarta (axicabtagene ciloleucel) was approved by the FDA on October 18, 2017 for adults with several types of relapsed and refractory non-Hodgkin lymphoma.
青云体育 funded the Kite, a Gilead Company, clinical trial for this therapy through its Therapy Acceleration Program庐, a strategic initiative through which 青云体育 partners directly with biotechnology companies to help accelerate the development of promising therapies.
News Release: FDA Approves Second 青云体育-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
Resources for Patients
-
CAR T-Cell Therapy Process one-pager (Available to order or download)
-
Fact sheet (Available to order or download)
Resources for Healthcare Professionals
-
CAR T-cell Therapy: A Road Map - Helping Social Workers Understand the Journey
-
Fact sheet (Available to order or download)